During the past decade, CH Annecy Genevois - Hématologie A3 conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "CH Annecy Genevois - Hématologie A3" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Janssen, LP" with 1 trials as a collaborator and "Janssen-Cilag Ltd." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "CH Annecy Genevois - Hématologie A3" are "Fit Patients" (1 trials), "Intermediate Risk Chronic Lymphocytic Leukemia" (1 trials), "Relapsed or Refractory Chronic Lymphocytic Leukemia" (1 trials) and "Risk-Adapted and MRD-Driven Strategy" (1 trials). Many other conditions were trialed in "CH Annecy Genevois - Hématologie A3" in a lesser frequency.

Most popular intervention types in "CH Annecy Genevois - Hématologie A3" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Daratumumab" (1 trials), "FCR" (1 trials), "Ibrutinib" (1 trials) and "venetoclax and ibrutinib (I+VEN)" (1 trials). Other intervention names were less common.

The vast majority of trials in "CH Annecy Genevois - Hématologie A3" are 2 trials for "All" genders.

Currently, there are NaN active trials in "CH Annecy Genevois - Hématologie A3". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in CH Annecy Genevois - Hématologie A3, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in CH Annecy Genevois - Hématologie A3, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".